Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
October 03 2022 - 8:30AM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing next-generation multifunctional biotherapeutics,
today announced that management will participate in upcoming
investor conferences:
- Stifel 2022 Healthcare Conference. Zymeworks’ management
will participate in one-on-one meetings and present on November
15th – 16th in New York, NY.
- Jefferies London Healthcare Conference. Zymeworks’
management will participate in one-on-one meetings and present on
November 15th – 17th in London, United Kingdom.
In addition, Zymeworks will present an update on its preclinical
research programs at an Early R&D day on October 20th, 2022,
in New York, NY. At this event, led by Paul Moore, PhD,
Zymeworks’ Chief Scientific Officer, we plan to present data from
multiple preclinical product candidates built upon our
industry-leading multispecific and next-generation TOPO1i based ADC
platforms as well as an update to our future scientific vision.
All presentations and webcasts will be available on Zymeworks’
website at http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of
next-generation multifunctional biotherapeutics. Zymeworks’ suite
of therapeutic platforms and its fully integrated drug development
engine enable precise engineering of highly differentiated product
candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a
novel Azymetric™ HER2-targeted bispecific antibody currently being
evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials
globally as a targeted treatment option for patients with solid
tumors that express HER2. Zymeworks’ second clinical candidate,
zanidatamab zovodotin (ZW49), is a novel bispecific HER2 ‑targeted
antibody-drug conjugate currently in Phase 1 clinical development
and combines the unique design and antibody framework of
zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and
cytotoxin. Zymeworks is also advancing a deep preclinical pipeline
in oncology (including immuno-oncology agents) and other
therapeutic areas. In addition, its therapeutic platforms are being
leveraged through strategic partnerships with global
biopharmaceutical companies. For more information on our ongoing
clinical trials visit www.zymeworksclinicaltrials.com. For
additional information about Zymeworks, visit www.zymeworks.com and
follow @ZymeworksInc on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221003005320/en/
Investor Inquiries: Jack Spinks (604) 678-1388 ir@zymeworks.com
Media Inquiries: Diana Papove (604) 678-1388
media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Jul 2023 to Jul 2024